🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Lacuna Pharma Pty Ltd” Clear

  1. bimekizumab

    Lacuna Pharma Pty Ltd

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  2. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  3. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  4. brivaracetam, brivaracetam, brivaracetam, brivaracetam

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  5. sotatercept, PL1 - Powder for injection

    Lacuna Pharma Pty Ltd

    Therapeutic confirmatory (phase III)

    phase 3 small molecule active

    1 trial

  6. sotatercept, sotatercept

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  7. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  8. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    tardive dyskinesia

    phase 2 small molecule active

    1 trial

  9. (+)-α-DIHYDROTETRABENAZINE, ADE513 placebo

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  10. -

    Lacuna Pharma Pty Ltd

    Myocardial Infarction, Acute Heart Failure, Left Sided

    phase 2 small molecule active

    1 trial

  11. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  12. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. 0.9% Sodium Chloride for Injection (Fresenius Kab) sourced locally by sites, AP-101

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  14. A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

    phase 2 other active

    1 trial

  15. A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 2 other active

    1 trial

  16. A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 other active

    1 trial

  17. ABO-102, ABO-102, ABO-102

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA

    phase 2 small molecule active

    1 trial

  18. AC102-Suspension 12 mg/ml, placebo gel, Placebo matching Prednisolone, Prednisolon 10 mg GALEN®

    Lacuna Pharma Pty Ltd

    Idiopathic Sudden Sensorineural Hearing Loss

    phase 2 small molecule active

    1 trial

  19. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  20. ADX-038

    Lacuna Pharma Pty Ltd

    Complement-Mediated Kidney Disease

    phase 2 small molecule active

    1 trial

  21. ADX-038, Sodio cloruro Galenica Senese 0,9% solvente per uso parenterale

    Lacuna Pharma Pty Ltd

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  22. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  23. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  24. ALDARA 5% cream, Keramod® gel

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources